CLINICAL TRIALS PROFILE FOR DIFLUNISAL
✉ Email this page to a colleague
All Clinical Trials for diflunisal
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00294671 ↗ | The Effect of Diflunisal on Familial Amyloidosis | Completed | Food and Drug Administration (FDA) | Phase 2/Phase 3 | 2006-02-01 | The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy. Funding Source - FDA Office of Orphan Products Development (OOPD); National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00294671 ↗ | The Effect of Diflunisal on Familial Amyloidosis | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2/Phase 3 | 2006-02-01 | The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy. Funding Source - FDA Office of Orphan Products Development (OOPD); National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00294671 ↗ | The Effect of Diflunisal on Familial Amyloidosis | Completed | Boston University | Phase 2/Phase 3 | 2006-02-01 | The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy. Funding Source - FDA Office of Orphan Products Development (OOPD); National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT01432587 ↗ | The Effect of Diflunisal on Familial Transthyretin Amyloidosis | Completed | Umeå University | 2011-08-01 | An ongoing trial of diflunisal has been closed for enrollment, thus, patients suitable for the study can no longer participate or receive treatment by diflunisal; and patients, who have participated in the trial can not continue their treatment. The investigators want to continue to monitor the effect of the drug on transthyretin (TTR) amyloidosis in an open label observational study. Primary endpoint will be a composite score of the manifestations of the disease (Kumamoto scale) and secondary end points will be measurements of neurological impairment, heart involvement and nutritional status. | |
| NCT01663922 ↗ | Boceprevir and Ucalm (St John&Apos;s Wort) | Completed | University of Liverpool | Phase 1 | 2012-08-01 | The purpose of the study is to look at whether taking a new medication for hepatitis C (boceprevir) together with a herbal remedy commonly used for the treatment of depression (SJW) has any effect on the levels of boceprevir in the blood, compared to when boceprevir is taken on its own. Treatment of hepatitis C genotype-1, has recently been significantly improved with the addition of a new class of drugs called protease inhibitors (PIs). Boceprevir belongs to this class of antiviral drugs and it is administered in combinations with other drugs to treat hepatitis C. One of the common side effects of treatment for hepatitis C is low mood (depression) for which treated patients may self-medicate with preparations containing St. Johns Wort (SJW). SJW is known to cause drug interactions, so taking SJW at the same time as boceprevir may result in a change in how both of these drugs usually work. It is therefore important to find out if the levels of boceprevir in the blood are significantly affected by taking SJW. The study aims to help us understand whether it will be safe to take SJW whilst being simultaneously treated for hepatitis C with boceprevir. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for diflunisal
Condition Name
Clinical Trial Locations for diflunisal
Trials by Country
Clinical Trial Progress for diflunisal
Clinical Trial Phase
Clinical Trial Sponsors for diflunisal
Sponsor Name
